Search research articles
Contact Us
Filters
Showing results (71-80 of 181) with videos related to
Page
of 19
Sort By:
Blood
|
July 30, 2010
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian, Farhad Ravandi, Susan O'Brien, et al.
International Journal of Cancer
|
July 20, 2017
Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells
Uri Rozovski, David M Harris, Ping Li, et al.
American Journal of Hematology
|
July 29, 2016
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
Preetesh Jain, Rashmi Kanagal-Shamanna, William Wierda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)
Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer
|
December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
Thomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Cancer
|
August 27, 2009
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
Deborah A Thomas, Hagop M Kantarjian, Wendy Stock, et al.
Leukemia & Lymphoma
|
October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini, Preetesh Jain, Long Trinh, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Nature Reviews. Clinical Oncology
|
February 14, 2018
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 181) with videos related to
Sort By:
Page
of 19
Blood
|
July 30, 2010
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian, Farhad Ravandi, Susan O'Brien, et al.
International Journal of Cancer
|
July 20, 2017
Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells
Uri Rozovski, David M Harris, Ping Li, et al.
American Journal of Hematology
|
July 29, 2016
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
Preetesh Jain, Rashmi Kanagal-Shamanna, William Wierda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)
Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer
|
December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
Thomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Cancer
|
August 27, 2009
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
Deborah A Thomas, Hagop M Kantarjian, Wendy Stock, et al.
Leukemia & Lymphoma
|
October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini, Preetesh Jain, Long Trinh, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Nature Reviews. Clinical Oncology
|
February 14, 2018
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Page
of 19